Dr Lal Pathlabs Ltd Management Discussions

Economy

Global Economic Review

In CY 2024, the global economy achieved a steady growth of 3.2%. The global economy successfully overcame significant economic obstacles, such as sustained geo-political tensions, geo-economic fragmentation and uncertainties in trade policy. The European economy saw subdued growth as it grappled with geo-political upheavals, low consumption, rising costs of living and weak manufacturing exports particularly in Germany. The US economy showcased steady growth owing to a strong labour market, high corporate earnings and high employability. During the reporting year, the Emerging Market and Developing Economies (EMDE) grew by 4.3% in comparison to the advanced economies that grew by 1.8%. The growth in the global economy was further supported by a steady fall in the inflation level from 6.7% in CY 2023 to 5.8% in CY 2024. This was facilitated by timely interventions by the central governments across the globe and falling energy price levels.

The global economy is expected to grow at a slightly lower of 2.8% in CY 2025 and 3.0% in CY 2026. The global inflation level is expected to further decline to 4.2% in CY 2025 and 3.5% in 2026 which will enhance growth and positively impact market sentiments. The recent escalation of US trade tariffs which have the global trade activity and disrupted the supply chain can potentially lower the global economic growth as well as the Indias economic growth. The slowdown in major economies like China continue to pose threats and escalating tariff wars continue to pose threats, accommodative monetary and fiscal policies implemented by Central banks and Governments around the world are expected to create an atmosphere conducive to growth.

Indian Economic Review

Amidst the volatile global economic landscape, the Indian economy exhibited a strong performance during the year under review. Indian economy, one of the fastest-growing economies in the world, is expected to grow by 6.5% in FY 2025. Inflation level dropped from 5.4% in FY 2024 to 4.9% in FY 2025, enhancing consumer confidence and spending, especially in rural areas The rural consumption remained robust during the reporting year and the investment activities in India gained momentum. This growth in investment activities can be attributed to the transformation in the business environment led by the timely interventions by the Indian Government through relevant schemes and policies. The Production-Linked Incentive (PLI) scheme, along with the global business strategy of China+1, has resulted in the holistic development of various industries in the economy. Additionally, in FY 2025, India attracted USD 55.6 billion in FDI, marking an increase from the previous fiscal year, which played a critical role in driving the growth and development of the economy.

In the years ahead, the Indian economy is anticipated to experience positive growth, especially supported by strong investment activities and increased public expenditure by the Government of India. The revision in the income tax slabs is expected to augment disposable income and drive consumer spending.

Indian Diagnostic Industry

The diagnostic laboratories serve as an integral component of the healthcare system. They play a crucial role in assisting the decision-making process regarding patients health. Through varied diagnostic tests and procedures, these laboratories assist healthcare providers to arrive at correct diagnoses. Additionally, the Indian diagnostic sector is witnessing transition from a fragmented network of isolated labs to a structured and scalable ecosystem, with national and regional players expanding their geographical presence. Heightened demand for high-quality healthcare, augmented consumer awareness and progress in technology is further bolstering this transition in the industry. Digitisation, automation and AI-powered innovations are elevating the efficiency and accuracy of the Indian diagnostic industry. Further to this, the growth in the Indian diagnostic industry can be attributed to the growing geriatric population, increasing health awareness among individuals, advancement in diagnostic technologies and a changing lifestyle. Unhealthy lifestyle is elevating the incidence of chronic diseases, creating the need for regular diagnostic monitoring.

In addition to this, the growth of the diagnostic industry in India was driven by supportive policies and schemes introduced by the Indian Government, such as, Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) and the PM Ayushman Bharat Health Infrastructure Mission (ABHIM). AB-PMJAY was initiated to offer comprehensive secondary and tertiary care hospitalisation benefits to more than 12 crore families.² This scheme includes a comprehensive coverage of medical procedures and includes the speciality areas, such as, General medicine, Surgery, Oncology and Cardiology. Under this scheme, the beneficiaries are entitled to free drugs, diagnostic procedures and food. ABHIM, a centrally sponsored scheme was initiated with an outlay of INR 64,180 crore.³ The objective of the scheme was to develop primary, secondary and tertiary healthcare systems. Further, it ensured the strengthening of existing national institutions and the creation of new institutions for the detection and cure of novel diseases.

Further to this, Ayushman Bharat Digital Mission enables the digital consultants to allow medical practitioners the access to patients records. This promotes digital health solutions of hospitals across the country, it making the healthcare services easily accessible to the patients.

The diagnostic industry in India is known for its cost-effective services in comparison to the global diagnostic industry. Within the diagnostic lab industry, the diagnostic chain segment has an important role. The diagnostic chain features a strong network of diagnostic centres and laboratories across different regions. The key players of the industry are expanding their network and logistical facilities. This expansion is augmenting the accessibility of diagnostic services for patients in tier I, tier II cities and beyond.

Additionally, the rise in the number of medical institutes and research centres has further supported the growth of diagnostic services.

Key factors driving the growth of the Indian diagnostic industry

Population growth

After surpassing Chinas population, India is the worlds most populous country, and it is anticipated to remain the most populous country in the world throughout the century. This is expected to support the growth of the diagnostic industry by expanding the demand for curative diagnostics, preventive healthcare and chronic disease management to meet the increasing healthcare needs.

Growing geriatric population

The Indian demograph is experiencing a rise in the number of the geriatric population in India. By 2036, it is anticipated that the number of individuals above 60 years will grow significantly. This change in the Indian demographics is anticipated to increase demand for diagnostics for chronic disease management, preventive healthcare, and regular diagnostic testing tailored to elderly health needs.

Healthcare infrastructure

With increased capital allocation for the healthcare sector in the Budget 2025-26, the governments focus is to improve the healthcare infrastructure in India. Further to this, the number of hospital beds is anticipated to rise at a CAGR of 7.99% by 2030. This will help the diagnostic centres to offer better services to the patients, thereby expanding their demand by effectively meeting the patients requirements.

Growth in medical education capacity

The Indian government has proposed to add more medical seats across medical colleges and hospitals. In the coming years, this will result in an increased number of trained healthcare professionals available to offer quality diagnostic services.

Diagnostic intensity

In Tier 2, 3, and 4 towns, people are increasingly choosing to undergo diagnostic testing before starting any medication. This shows a shift in healthcare behaviour, where individuals now prefer to understand their health conditions through proper tests first and then follow treatment based on accurate reports.

Outlook

The Indian diagnostic industry is anticipated to exhibit a positive growth trajectory and grow at a Compound Annual Growth Rate (CAGR) of ~8-10% from 2025-2030. This growth in the industry is envisioned to be directed by the rise in disposable income, a growing population and heightened health awareness, which will further create the demand for quality healthcare services, including diagnostic services.

Company Overview

Dr. Lal PathLabs

Dr. Lal PathLabs was established in 1949. The company is well known and widely regarded for consistently introducing pioneer tests and technologies in Indian Diagnostics Market. The Company has launched multiple "Center of Excellence" in recent times focusing on various specialities such as Genevolve (Genetic Testing ), L-ACE(Autoimmunity), L-CoRD (Reproductive Diagnosis) & L-CID (Infectious Diseases) defining the steps towards Medical Excellence. The Company has expanded its test offering which include basic preventive health packages "SwasthFit" to most advanced investigations such as Comprehensive Genomic Profile, Myeloid testing for Haematological Malignancies & Amyloid Typing Solutions. The Company is actively working to Introduce the Artificial Intelligence based algorithm in multiple diagnostics areas such as Histopath & Haematology to improve the efficiency, accuracy and reproducibility of results.

Dr. Lal PathLabs is considered the largest diagnostics chain, in terms of both revenue and presence, in the country, with a pan-India presence and a consistent track record of quality and growth.

Operational Highlights

Key achievements in FY 2025

Dr. Lal PathLabs continued to strengthen its operations and reach. The company added 18 new laboratories and over 850 new patient service centers across the country, making diagnostic services more accessible. Around 80 new tests were launched to meet growing healthcare needs. Approximately 30 million patients were served during the year, highlighting the companys strong presence. A strong focus on geographic expansion and test mix helped the company deliver higher realisation per patient. IT systems at Suburban Diagnostics were standardised to improve efficiency. Sustained investment in digital infrastructure has helped the company gain flexibility and efficiently deliver services to a larger number of patients. The company also made important digital investments to enhance patient experience and operational strength.

Opportunities and Threats

Opportunities

Demographic

Growing population is creating a large and expanding market for diagnostic services. In addition, the rising number of people aged over 40, who are more likely to avail diagnostics services, is increasing the need for regular health checks and disease management. This change highlights how important diagnostic testing has become, acting as a key part of both preventive care and ongoing treatment.

Geriatric population: The expected growth in the aged population coupled with heightened health awareness is anticipated to facilitate the growth of the Company

Rising disposable Income

Rising disposable incomes are leading people to focus more on their health and spend on better quality healthcare services, including reliable diagnostic testing. This trend is also supported by growing awareness of how important accurate and timely diagnostics are for better health outcomes. Dr. Lal PathLabs understands this change and is committed to offering accessible, affordable, timely, and high-quality diagnostic services.

Medical Infrastructure expansion

The growing medical infrastructure in Tier II towns, with more hospitals and clinics coming up, is increasing the demand for a wider range of diagnostic services, including specialised tests. As healthcare access spreads beyond urban areas, there is a greater need for advanced diagnostic services in these areas. This creates a big opportunity for organised diagnostic chains like Dr. Lal PathLabs. The company is focusing on expanding its network of labs and patient service centers centres in these towns and surrounding feeder towns to meet the rising demand.

Health awareness

Heightened health-consciousness will drive the need for diagnostic services and advanced healthcare solutions, thereby offering growth opportunities for Dr. Lal PathLabs by providing personalised health checkup packages across various price levels such that a wider range of patients are catered.

Preventive checkups

There is a rising focus on preventive healthcare as people become more aware of the importance of staying healthy before illness strikes. This has led to a growing demand for preventive checkups and wellness packages. Dr. Lal PathLabs "Swasthfit" bundled test program is designed to meet this demand for proactive health management. The program has seen strong growth, outpacing the overall business growth. In response to this trend, the company is expanding its range of bundled packages to offer even more options for people seeking to maintain their health.

Expanding geographic presence

There are significant opportunities to expand into underserved areas, especially in Tier 3 and Tier 4 towns across India. Dr. Lal PathLabs is focusing on a two-pronged expansion strategy. This includes organic growth by opening new labs and collection centers in these regions, as well as inorganic growth through strategic acquisitions to strengthen its presence in key markets like the West and South. The goal of this expansion is to bring high-quality diagnostic services closer to people in these areas.

Threats

Pricing control

The imposition of pricing caps on routine diagnostic tests by regulatory bodies could put pressure on the revenue and profitability of diagnostic service providers, particularly for high-volume tests. While Dr. Lal PathLabs focuses on a diverse range of tests, including specialised ones, limitations on the pricing of common tests may affect its overall financial performance.

Government Infra Strengthening

An increasing emphasis on strengthening government healthcare infrastructure and offering free diagnostic services at public health facilities presents a potential threat to private diagnostic players. As more people turn to public healthcare for basic tests, it could impact the volume of business for private providers, especially in low-cost test categories in semi-urban areas.

Rising competition in specialized business

Diagnostic companies focusing on niche or specialised segments are growing in scale and expertise, attracting patients and healthcare providers seeking targeted diagnostic solutions. This trend could create competition for Dr. Lal PathLabs broader test menu, especially in highly specialised areas. In response, the company is expanding its offerings in advanced diagnostics and genomics.

Investment Surge

Fresh Private Equity (PE) and Venture Capital (VC) investments in the diagnostics sector could lead to heightened competition. These investments enable new and existing players to expand rapidly by establishing more labs, acquiring advanced technology, and offering a wider range of specialised tests. Moreover, they may adopt aggressive pricing strategies and invest heavily in marketing to attract customers. This influx of capital will increase competition, putting pressure on established players like Dr. Lal PathLabs.

Business Targets and Strategies

Key strategies implemented to support the long-term growth of Dr. Lal PathLabs

Focus on strengthening Medical Excellence/ Expertise

Strengthening its leadership position in the core markets of North India, including Delhi NCR, through

(i) Better service

(ii) Newer Offerings

(iii) Upgrading Infrastructure

(iv) More Convenience

Enhancing its digital infrastructure through the deployment of AI, data analytics to enhance the patients experience and offer customised services.

Enhancing the high-end test portfolio of super specialty.

Implement initiatives such as the cluster city approach, to increase the volumes in high-potential markets.

Region wise revenue breakup

(in percentage)

ALIGN=RIGHT>5.94

Particulars	FY 2025	FY 2024
Delhi NCR	31.08	31.11
UP & UK	18.62	18.52
Rest of North India	13.20	12.87
East India	14.55	14.50
West	14.62	14.80
South	5.62
Others	2.31	2.26
Total	100.00	100.00

Revenue

In FY 2025, the consolidated revenue of the Company was 24,614 Million, highlighting Y-o-Y growth of 10.5%

Costs

The key cost components of Dr. Lal PathLabs include expenses related to reagents and chemicals, personnel, fees associated with collection centres, logistics, information technology and infrastructure. The cost management is a key focus area for the Company.

EBITDA

For the reporting year, the EBITDA was 6,956 million, whereas in FY 2024, it was 6,092, highlighting a growth of 14.2%.

PBT and PAT

PBT of the Company was 6,248 million in FY 2025 in comparison to 5,055 million in FY 2024, highlighting a growth of 23.6%.

In FY 2025, PAT of the Company was INR 4,923 million as compared to INR 3,632 million in FY 2024, highlighting a growth of 35.9%.

Cash and bank

In the reporting year, the cash and cash equivalents of the Company was 12,290 million, whereas, in FY 2024, it was 8,769 million.

	Consolidated
Particulars	FY 2025	FY 2024	% Variance	Reason for variance
Debtors turnover (times)	30	30	-1.0%	-
Inventory turnover (times)	13	13	3.3%	-
Interest coverage ratio	29.0	18.2	59.3%	Improvement on account of increase in earnings during the year and reduction of interest cost due to repayment of borrowings
Current ratio	3.4	2.4	39.4%	Higher current assets in reporting year and lower current liabilities
Debt equity ratio	0.07	0.13	-45.7%	Reduction on account of repayment of borrowings during the year
Operating profit Margin (%) *	22.5	20.9	7.6%	-
Net profit margin (%)	19.3	15.8	22.1%	Increased operational efficiencies resulted in improvement of net margin

*Formula: (EBIT-Interest Income)/Revenue

Human Resource

The Company believes its strong and skilled professionals to be critical in driving the long-term growth of the Company. In FY 2025, the Company had 6,000+ (Group wise) workforce and ensured them a positive, safe and engaging work environment. In addition, the learning and development activities implemented by the Company help the workforce to upskill themselves and remain relevant to industry demand. During FY 25, Dr. Lal PathLabs enhanced employee engagement by focusing on wellness, development, and recognition. Programmes were built around five wellness dimensions — Physical, Emotional, Financial, Occupational, and Spiritual. The company launched four Employee Experience Clubs to promote engagement across different areas, organised monthly reviews, cultural celebrations, and volunteering events like blood donation drives. A new recognition programme, RISE, replaced the earlier system, leading to a 90% increase in employee recognitions. Emotional well-being was supported through the ‘1to1 Help Employee Assistance Programme, along with virtual yoga and meditation sessions. Dr. Lal PathLabs promoted a safe and equitable workplace by strengthening inclusive hiring through the SAMATVA programme, onboarding 30 persons with disabilities and providing them with tailored support. Sensitisation sessions were conducted to build awareness and inclusivity. The company maintained strict ethical standards through its Code of Conduct and Whistleblower Policy and ensured operational safety through regular audits and quality certifications like NABL and CAP. Efforts towards environmental responsibility and enhanced cybersecurity further contributed to a safe and healthy working environment.

In FY 25, Dr. Lal PathLabs expanded learning and development through a blended approach of instructor-led training, online courses, coaching, and mentoring. About 74% of employees were covered across 33 programmes, focusing on behavioural, technical, compliance, leadership, and induction training. Key initiatives included structured onboarding journeys like Aarambh and Parichay, leadership development through FLIP, technical skilling through EDGE and HUNAR, and on-the-job learning under MedNxt and PROJECT NEEV, building strong capabilities across different roles in the organisation.

Environment, Social and Governance

Environmental sustainability remains a key area of focus for the Company. The Company ensures its operations have minimised impact on the environment. Further, Dr. Lal PathLabs implemented several initiatives in FY 2025 to promote sustainability. Additionally, the Company ensures value creation for its stakeholders, such that it contributes towards capacity building and creating resources for the underserved sections in society. In FY 25, Dr. Lal PathLabs continued to focus strongly on environmental sustainability as part of its long-term business goals. The company worked on reducing its environmental footprint by taking steps to conserve energy, save water, manage waste properly, and lower harmful emissions across its operations. To conserve energy, the company increased its use of renewable sources by expanding its solar energy capacity to 3.18 MW. Major solar projects included expanding the solar plant in Qutubgarh and installing solar panels in Lucknow and Noida. Dr. Lal PathLabs also replaced old air conditioning systems with inverter-based units that are more energy efficient and installed Power Capacitor Banks to reduce energy loss. LED lighting continued to be introduced across facilities to further save energy.

In water conservation, the company reused RO wastewater for non-drinking purposes like washrooms and gardening. All laboratories had Effluent Treatment Plants (ETPs) to properly treat wastewater before it was either reused or safely released. Smart water meters were also being installed at various locations to monitor and reduce water usage.

For waste management, Dr. Lal PathLabs followed strict practices to separate, treat, and safely dispose of both hazardous and non-hazardous waste. Special attention was given to handling biomedical waste, with the continued use of autoclaves for sterilisation. The company also used biodegradable bags for sample collection to reduce plastic waste.

To reduce emissions, Dr. Lal PathLabs upgraded its older diesel generator sets to newer, more efficient models that meet the latest environmental standards. HVAC systems were optimised by maintaining room temperatures at 24?C to save energy. The emissions company also saved over 1.6 million kilograms of CO2 by using solar energy and introduced electric bikes for sample collection to further cut down pollution.

Data Privacy

The protection ofdata for its customers and clients forms an integral component for Dr. Lal PathLabs. This is undertaken by the implementation of data loss prevention measures, software security and threat intelligence.

Data loss prevention

In FY 25, Dr. Lal PathLabs used various tools to prevent the loss of sensitive information. These included data loss prevention (DLP) technologies that help control how data is shared and accessed. The Company also used rights management systems to make sure that only authorised people could access important data. Advanced cybersecurity solutions like Cloud Access Security Broker (CASB), Endpoint Detection and Response (EDR), Advanced Threat Protection (ATP), and email protection were used to stop new types of cyber threats. A centralised data system was also set up to improve reporting and patient care, especially for chronic conditions, which required even stronger data protection.

Software security

To keep its systems safe, Dr. Lal PathLabs regularly carried out vulnerability assessments and penetration tests on its IT applications and cloud platforms. These tests helped find and fix any security gaps. The company also reviewed the coding and system settings of its important software to ensure they were properly secured. Most of its applications, including patient and business portals, were hosted on Microsoft Azure cloud, which added another layer of security. A new cloud-based ERP system was also introduced to improve both security and performance.

Threat intelligence

Dr. Lal PathLabs used a threat intelligence platform to look out for risks like data leaks, fraud, and exposed user credentials across different online platforms. A 24x7 security operations center was set up to monitor threats continuously and act fast if any were found. The company also had a Cyber Crisis Management Plan ready to deal with serious cyber incidents. In addition, by taking part in the Ayushman Bharat Digital Mission and earning certifications, the company followed national standards to ensure health data security.

Company Outlook

• A strong focus on adhering to the highest quality standards and aligning with medical accreditations will remain the key focus of the Company, such that its reputation as a reliable and accurate diagnostics in India. Along with this, consistent efforts are made to improve the experience it offers to its patients by making the entire process smoother and convenient. The Company focuses on improving its overall operational efficiencies through implementing cost reduction strategies, improving the IT system and delivering quicker test results.

• To strengthen the medical excellence such that it enhances the Companys credibility and sustainable growth. This will be achieved through focusing on the quality, integration of advanced technologies and maintaining strong network facilities.

• Fortifying the Companys presence across key geographies will offer diversified revenue generating source to the Company. Such expansion, especially in tier 1 and metro cities will further strengthen its position as the trusted diagnostic partner. Further to this, it is also consistently developing its presence in the tier 2 and tier 4 cities in Northern and Eastern India.

• Leveraging technologies across its value creation, including enhancing patient experience and streamlining its operational efficiencies through adopting sophisticated logistics and data management systems. This initiative remains strategic and integral in driving security and delivering innovative services.

• Through ramping up the infrastructure activities, the Company will secure its access to newer micro markets and expansion to new geographies. Further to this, it will also enhance both the revenue generated and the volume of patients in the coming years, backed by the upgradation of laboratory infrastructure

• Increasing marketing expenditure will help the Company by reaping the benefits through supporting the upgradation in the existing laboratories and its infrastructure. This will also support the Companys strategy to expand its networking and serve a large market

• To strengthen its presence in South India, the Company is exploring acquisitions alongwith organic growth opportunities. Moreover, the Company remains positive of its strong balance sheet that will support acquisitions in the coming years

• Indian diagnostic testing sector is unorganised, therefore the Company aims to fill this gap by providing higher testing infrastructure and integrating advanced technologies such that the quality is not compromised and a larger scale of patients can access it.

Risks and Concerns

Risk Category	Risk description	Mitigation strategy
Economic risk	Fluctuations in economic parameters, such as the level of inflation and alterations in governmental policies will undermine the operational efficiency of the Company	The Company has ability to transfer a part of infilation to the end customer thereby mitigating the margin contraction.
Competition risk	Dr. Lal PathLabs operates in an unorganised industry which heightens the chances of new players entering the industry. These players operate at a competitive price which further undermines the market position of the existing players in the industry.	The Company focuses on expanding its presence such that it can maintain its strong position in the industry. Further, to realise its strong growth and expansion potentials, it continuously invests in high-quality standards, as well as maintains strong performance.
Technology risk	To sustain in the competitive business environment, it is essential for the Company to integrate cutting-edge technology such that its operations remain unscathed.	Dr. Lal PathLabs integrates advanced technology to yield faster and better results. Further to this, accelerated technological innovations will help the Company to mitigate technology risk.
People risk	The Company needs to retain its skilled professionals who can help the Company to surpass the challenges and attain a sustainable growth.	Dr. Lal PathLabs implements effective strategies to retain qualified professionals. It provides competitive benefits, training programmes and a positive and engaging working environment. Additionally, the cohesive work culture and transparency within the Company support the retention of its skilled workforce. .
Operational risk	Risk arising from failure to maintain the testing procedure, human errors can adversely affect its operations	The risks associated with operational failure are mitigated by the Company by standardisation of its operating procedure and equipment maintenance. In addition to this, qualified staff and the integration of advanced technologies also help the Company to effectively mitigate the operational risk.

Internal Control Systems and their Adequacy

The Company has established a comprehensive internal controls framework, which includes thoroughly documented policies and procedures spanning financial and operational aspects. This framework guarantees the upkeep of precise accounting records and offers a reasonable level of confidence in the reliability of financial reporting. Additionally, it facilitates efficient monitoring of operations, protects assets from unauthorised use or loss and ensures compliance with relevant regulations.

Auditors

During the 28th Annual General Meeting held on June 30, 2022, the Members of the Company reaffirmed the appointment of Deloitte Haskins & Sells as Statutory Auditors for five years. Deloitte Haskins & Sells is a firm registered with the Institute of Chartered Accountants of India under Registration No. 117366W/W-100018.

Cautionary Statement

The statement provided in this Management Discussion and Analysis acknowledges that the Companys objectives, projections, estimates, expectations, or predictions may be considered as ‘forward-looking statements under applicable securities laws and regulations. It cautions that actual results may differ significantly from those expressed or implied. Various important factors, such as global and Indian demand and supply conditions, prices of finished goods, availability and prices of input materials, cyclical demand and pricing in the Companys main markets, changes in government regulations and tax regimes, economic developments in India and other relevant countries, as well as factors like litigation and labour negotiations, can impact the Companys operations. The Company does not assume any responsibility to publicly amend, modify, or revise the forward-looking statements based on subsequent developments, information, events, or any other circumstances.